Literature DB >> 15215106

Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.

Silvia M Uriarte1, Robert E Molestina, Richard D Miller, Jorge Bernabo, Alicia Farinati, Kumiko Eiguchi, Julio A Ramirez, James T Summersgill.   

Abstract

The anti-inflammatory activities of three quinolones, levofloxacin, moxifloxacin, and gatifloxacin, were investigated with an in vitro model of transendothelial migration (TEM). Human umbilical vein endothelial cells (HUVEC) were seeded in Transwell inserts, treated with serial dilutions of antibiotics, infected with Chlamydia pneumoniae, or stimulated with tumor necrosis factor alpha (TNF-alpha). Neutrophils or monocytes were also preincubated with serial dilutions of each antibiotic. TEM was assessed by light microscopic examination of the underside of the polycarbonate membrane, and levels of interleukin-8 (IL-8) and monocyte chemotactic protein 1 (MCP-1) were measured by enzyme-linked immunosorbent assay. In HUVEC infected with C. pneumoniae or stimulated with TNF-alpha, all fluoroquinolones significantly decreased neutrophil and monocyte TEM, compared to antibiotic-free controls. Moxifloxacin and gatifloxacin produced a significant decrease in IL-8 in C. pneumoniae-infected and TNF-alpha-stimulated HUVEC; however, moxifloxacin was the only fluoroquinolone that produced a significant decrease in MCP-1 levels under both conditions. Results from this study indicate similarities in the anti-inflammatory activities of these fluoroquinolones, although no statistically significant decrease in chemokine secretion was observed when levofloxacin was used. Mechanisms of neutrophil and monocyte TEM inhibition by fluoroquinolone antibiotics are unknown but may be partially due to inhibition of IL-8 and MCP-1 production, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215106      PMCID: PMC434182          DOI: 10.1128/AAC.48.7.2538-2543.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  Possible interaction between new quinolones and immune functions in macrophages.

Authors:  Y Azuma; M Shinohara; N Murakawa; M Endo; K Ohura
Journal:  Gen Pharmacol       Date:  1999-05

Review 2.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 3.  Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?

Authors:  M T Labro
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

4.  Requirement for NF-kappaB in transcriptional activation of monocyte chemotactic protein 1 by Chlamydia pneumoniae in human endothelial cells.

Authors:  R E Molestina; R D Miller; A B Lentsch; J A Ramirez; J T Summersgill
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 5.  The fluoroquinolone antibacterials: past, present and future perspectives.

Authors:  P C Appelbaum; P A Hunter
Journal:  Int J Antimicrob Agents       Date:  2000-09       Impact factor: 5.283

6.  Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha.

Authors:  Silvia M Uriarte; Robert E Molestina; Richard D Miller; Jorge Bernabo; Alicia Farinati; Kumiko Eiguchi; Julio A Ramirez; James T Summersgill
Journal:  J Infect Dis       Date:  2002-05-17       Impact factor: 5.226

Review 7.  Pathogenetic concepts of acute coronary syndromes.

Authors:  Roberto Corti; Valentin Fuster; Juan Jose Badimon
Journal:  J Am Coll Cardiol       Date:  2003-02-19       Impact factor: 24.094

8.  Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Authors:  Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell
Journal:  JAMA       Date:  2003-10-01       Impact factor: 56.272

9.  Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

Authors:  Christopher M O'Connor; Michael W Dunne; Marc A Pfeffer; Joseph B Muhlestein; Louis Yao; Sandeep Gupta; Rebecca J Benner; Marian R Fisher; Thomas D Cook
Journal:  JAMA       Date:  2003-09-17       Impact factor: 56.272

Review 10.  Immunomodulatory effects of quinolones.

Authors:  Axel Dalhoff; Itamar Shalit
Journal:  Lancet Infect Dis       Date:  2003-06       Impact factor: 25.071

View more
  7 in total

1.  Berberine inhibits HEp-2 cell invasion induced by Chlamydophila pneumoniae infection.

Authors:  Li Jun Zhang; Li Jun Zhang; Wei Quan; Bei Bei Wang; Bing Ling Shen; Teng Teng Zhang; Yi Kang
Journal:  J Microbiol       Date:  2011-11-09       Impact factor: 3.422

2.  Chlamydia pneumoniae infection promotes vascular smooth muscle cell migration through a Toll-like receptor 2-related signaling pathway.

Authors:  Beibei Wang; Lijun Zhang; Tengteng Zhang; Haiwei Wang; Junxia Zhang; Junyan Wei; Bingling Shen; Xin Liu; Zhelong Xu; Lijun Zhang
Journal:  Infect Immun       Date:  2013-09-30       Impact factor: 3.441

3.  A three-dimensional in vitro model to demonstrate the haptotactic effect of monocyte chemoattractant protein-1 on atherosclerosis-associated monocyte migration.

Authors:  Neda Ghousifam; Hamid Mortazavian; Rudra Bhowmick; Yolanda Vasquez; Frank D Blum; Heather Gappa-Fahlenkamp
Journal:  Int J Biol Macromol       Date:  2016-12-29       Impact factor: 6.953

4.  Development of a mathematical model to describe the transport of monocyte chemoattractant protein-1 through a three-dimensional collagen matrix.

Authors:  Krisada Leemasawatdigul; Heather Gappa-Fahlenkamp
Journal:  Cardiovasc Pathol       Date:  2011-11-18       Impact factor: 2.185

5.  Advances in the prevention, management, and treatment of community-acquired pneumonia.

Authors:  Mathias W Pletz; Tobias Welte; Sebastian R Ott
Journal:  F1000 Med Rep       Date:  2010-07-22

Review 6.  Triclosan: An Update on Biochemical and Molecular Mechanisms.

Authors:  Mohammad A Alfhili; Myon-Hee Lee
Journal:  Oxid Med Cell Longev       Date:  2019-05-02       Impact factor: 6.543

7.  Putative Periodontal Pathogens, Filifactor Alocis and Peptoanaerobacter Stomatis, Induce Differential Cytokine and Chemokine Production by Human Neutrophils.

Authors:  Aruna Vashishta; Emeri Jimenez-Flores; Christopher K Klaes; Shifu Tian; Irina Miralda; Richard J Lamont; Silvia M Uriarte
Journal:  Pathogens       Date:  2019-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.